Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically requesting additional information from Wuhan Aimeson Life Science Co., Ltd. regarding its equity changes, shareholder status, and business operations [1][2][3] Group 1: Equity Changes - The CSRC requires Aimeson to clarify the basis for pricing in past capital increases and share transfers, including whether actual contributions were made and if there were any breaches of contribution obligations [1] - A significant equity transfer occurred in June 2016, where two shareholders transferred their shares at a price of 0, leading to a change in control; the reasons for this transfer need to be explained [1] - Historical instances of shareholding representation must be verified according to regulatory guidelines [1] Group 2: Shareholder Information - Aimeson must justify the reasonableness of the share prices for new shareholders over the past 12 months and confirm whether there are any conflicts of interest [2] - The company is required to disclose whether major shareholders, such as Guangzhou Kaipu and Suzhou Jinhui, have any domestic entities that are legally prohibited from holding shares [2] - Information regarding the identification of state-owned shareholders and the number of shareholders must be provided [2] Group 3: Business Operations - Aimeson needs to detail its business scope, including medical research, cell technology development, and gene diagnosis, confirming whether it has the necessary licenses and if its operations comply with foreign investment regulations [3] - The company must disclose its related transactions with Kaipu Biology and other entities, ensuring independence in personnel, business, assets, and finances [3] Group 4: Listing and Full Circulation - Aimeson is required to outline its plans for share subdivision and confirm whether this will affect the number of shares issued [3] - The company must ensure consistency between the filing materials and the prospectus regarding the issuance plan [3] - Information on whether shares held by participating shareholders in the "full circulation" are subject to pledges, freezes, or other rights defects must be provided [3] Group 5: Company Overview - Aimeson is a leading early cancer detection company focusing on high-incidence and high-mortality cancers, having developed a methylation-based early cancer detection technology [3] - The company offers two core products: Aixin Gan for liver cancer and Aiguang Le for urinary tract epithelial cancer, with Aixin Gan achieving a sensitivity of 92.33% and specificity of 93.35% in liver cancer detection [3] - Aiguang Le allows for non-invasive detection of urinary tract epithelial cancer using just 1 milliliter of urine, significantly improving efficiency and convenience compared to traditional methods [3]
艾米森拟港股上市 中国证监会要求补充说明股权变动等事项
Zhi Tong Cai Jing·2025-11-14 12:05